COMMON SHARE PURCHASE WARRANT XORTX THERAPEUTICS, Inc.Common Share Purchase Warrant • May 26th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • New York
THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (Eastern time) on __, 202[ ] (the “Termination Date”) but not thereafter, to subscribe for and purchase from XORTX Therapeutics, Inc., a company organized under the laws of British Columbia (the “Company”), up to ______ Common Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain Underwriting Agreement, dated [__], 2021, between the Company and A.G.P./Alliance Global Partners, as representative of the underwriters thereunder (the “Underwriting Agreement”). This
THIS EMPLOYMENT AGREEMENT is made as of the 1st day of January, 2018.Employment Agreement • May 26th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Alberta
Allen Davidoff, an individual residing in the City of Calgary, in the Province of Alberta (hereinafter called the "EMPLOYEE")
MASTER SERVICES AGREEMENTMaster Services Agreement • May 26th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Quebec
This Master Services Agreement (this " Agreement") is made as of the day of 2017, (the "Effective Date") by and between Cato Research Canada lnc., a Quebec corporation headquartered at 9900 Cavendish Boulevard, Suite 300, Saint-Laurent, Quebec, Canada H4M 2V2 ("CRC" ), and XORTX Pharma Corp., a form of organization with offices located at 4000, 421 7th Avenue SW, Calgary, Albe1ta, Canada T2P 4K9 ("XORTX"). Each of CRC and XORTX may be referenced to herein separately as a "Party" and collectively as the "Parties.'' As used in this Agreement, "Affiliate(s)" means any corporation, firm, partnership, or other entity which controls, is controlled by or is under common control with a Party. For the purpose of this definition, "control" shall mean the power to direct, or cause the direction of: the management and policies of an entity through the ownership, directly or indirectly, of at least fifty percent (50%) of the voting share capital of such entity or any other comparable equity, by con
SUBSCRIPTION AGREEMENTSubscription Agreement • May 26th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • Alberta
The undersigned (hereinafter referred to as the "Subscriber") hereby irrevocably subscribes for and agrees to purchase the number of units of the Corporation set forth below (the "Units") for the aggregate subscription price set forth below (the "Aggregate Subscription Price"), representing a subscription price of Cdn. $0.14 per Unit, upon and subject to the terms and-conditions set forth in "Terms and Conditions of Subscription for Units of the Corporation" attached hereto (the "Terms and Conditions", and together with this page and the attached exhibits, the "Subscription Agreement"). Each Unit will be comprised of one common share of the Corporation ("Common Share") and one Common Share purchase warrant of the Corporation ("Warrant"). Each Warrant entitles the holder to purchase one Common Share ('Warrant Share") at a price of Cdn. $0.25 per Warrant Share for a period of one year following the Closing Date (as defined herein), provided, however, that, if, at any time following the e
STRICTLY CONFIDENTIALAdvisory Agreement • May 26th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • New York
This letter (this “Agreement”) constitutes the agreement between XORTX Therapeutics, Inc. (the “Company”) and David Sans, Ph.D. (“Consultant”), that Consultant shall serve as the exclusive advisor for the purpose of establishing collaborations or clinical trials to study the effect of XORTX’s products, the Company’s small molecules (the “Product”), in patients across various clinical indications (the “Services”.)
Re: Side Letter to Master Services and Technology AgreementSide Letter to Master Services and Technology Agreement • May 26th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations
Reference is made to the Master Services and Technology Agreement by and between Prevail InfoWorks, Inc. ("InfoWorks") and XORTX Therapeutics, Inc. ("XORTX"), dated as of the date hereof (the "Agreement"). The purpose of this side letter agreement (this "Side Letter") is to memorialize and confim1 InfoWorks' , XORTX ' s and Prevail Partners LLC' s ("Partners") understanding with respect to the payment of the Contract Signature Payments under the Agreement. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Agreement.
MASTER SERVICE AND TECHNOLOGY AGREEMENTMaster Service and Technology Agreement • May 26th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations
INVESTIGATOR INITIATED-CLINICAL TRIAL AGREEMENTInvestigator Initiated Clinical Trial Agreement • May 26th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • New York
This Investigator-Initiated Clinical Trial Agreement ("Agreement") effective this 3rd day of August, 2020, (the "Effective Date") is by and between ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, a non-profit corporation, having its principal offices at One Gustave L. Levy Place, New York, NY 10029 ("INSTITUTION") and XORTXTherapeutics ("COMPANY"), a Canadian corporation, having its principal offices at Suite 4000, 421-7th Avenue Calgary, Alberta, Canada. INSTITUTION's faculty employee Steven Coca, M.D. ("PRINCIPAL INVESTIGATOR") shall be the Sponsor-Investigator under this Agreement, and shall conduct this Study as an employee of lnstitution and not as a party to this Agreement.
